Table 1.
Distribution of antimicrobial resistant phenotype among Gram-positive organisms by bacterial species and tested antimicrobial agents.
| Antimicrobial Category | Antimicrobial Agents | CoNS | Staphylococcus aureus | Enterococcus faecalis | Enterococcus faecium | Total | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N = 366 | (%) | N = 235 | (%) | N = 72 | (%) | N = 34 | (%) | N = 707 | (%) | ||
| Penicillins | PEN | 175 | (47.8) | 146 | (62.1) | 14 | (19.4) | 19 | (55.9) | 354 | (50.4) |
| OXA | 116 | (31.7) | 66 | (28.1) | NT | NT | 182 | (30.3) 1 | |||
| Fluoroquinolones | CIP | 52 | (14.2) | 39 | (16.6) | 12 | (16.7) | 8 | (23.5) | 111 | (15.7) |
| LVX | 141 | (38.5) | 77 | (32.8) | 28 | (38.9) | 12 | (35.3) | 258 | (36.5) | |
| Aminoglycosides | GEN | 145 | (39.6) | 78 | (33.2) | - 2 | - 2 | 223 | (37.1) 1 | ||
| HLG | NT | NT | 37 | (51.4) | 15 | (44.1) | 52 | (49.1) 1 | |||
| Macrolides | ERY | 164 | (44.8) | 83 | (35.3) | 23 | (31.9) | 10 | (29.4) | 280 | (39.6) |
| Lincosamides | CLI | 137 | (37.4) | 69 | (29.4) | - 2 | - 2 | 206 | (34.3)1 | ||
| Tetracyclines | TET | 88 | (24) | 43 | (18.3) | 12 | (16.7) | 7 | (20.6) | 150 | (21.2) |
| Folate pathway inhibitors | SXT | 96 | (26.2) | 53 | (22.6) | - 2 | - 2 | 149 | (24.8) 1 | ||
| Glycopeptides | VAN | 9 | (2.5) | 7 | (3) | 0 | 1 | (2.9) | 17 | (2.4) | |
| TEC | 59 | (16.1) | 33 | (14) | 6 | (8.3) | 3 | (8.8) | 101 | (14.3) | |
| Oxazolidinones | LZD | 18 | (4.9) | 7 | (3) | 0 | 0 | 25 | (3.5) | ||
| Lipopeptides | DAP | 23 | (6.3) | 20 | (8.5) | 7 | (9.7) | 0 | 50 | (7.1) | |
Abbreviations: CoNS, Coagulase-negative Staphylococcus; CIP, ciprofloxacin; CLI, clindamycin; DAP, daptomycin; ERY, erythromycin; GEN, gentamicin; HLG, high-level gentamicin; LVX, levofloxacin; LZD, linezolid; OXA, oxacillin; PEN, benzylpenicillin; SXT, trimethoprim-sulfamethoxazole; TEC, teicoplanin; TET, tetracycline; VAN, vancomycin; NT: not tested. 1 Percentages are calculated among the total tested organisms. 2 According to the Clinical & Laboratory Standards Institute CLSI, Enterococcus species susceptibility to low-level aminoglycoside, clindamycin and trimethoprim-sulfamethoxazole should not be reported, as they may appear active in vitro but are ineffective clinically.